Revenue
$5.00M
Fiscal year ended 2026-06-30Operating income
-$10.37M
Fiscal year ended 2026-06-30Free cash flow
-$7.43M
Fiscal year ended 2026-06-30Surrozen, Inc./DE (SRZN) reported revenue of $5.00M and net income of $50.18M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Surrozen, Inc./DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.00M | $5.00M | $528.00K | $983.00K | $983.00K | $983.00K | $655.00K | $10.00M | $0 | $0 |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$10.37M | -$10.46M | -$12.64M | -$10.88M | -$9.02M | -$9.55M | -$8.59M | $1.23M | -$9.05M | -$9.13M |
| Net income | $50.18M | -$127.50M | -$183.16M | -$71.64M | $39.75M | -$26.97M | -$28.04M | -$1.43M | -$25.26M | -$8.83M |
| Research & development | $8.48M | $9.33M | $8.99M | $7.77M | $6.04M | $6.56M | $5.35M | $5.20M | $5.34M | $5.25M |
| Weighted-average diluted shares | shares 23.15M | Unavailable | Unavailable | Unavailable | shares 8.54M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | $0 | $0 | Unavailable | Unavailable | $0 | $0 | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-0.41 | $-11.65 | Unavailable | $-8.36 | $2.55 | $-7.43 | Unavailable | $-0.44 | $-7.99 | $-4.24 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $6.89M | $6.13M | $4.18M | $4.09M | $3.96M | $3.98M | $3.90M | $3.57M | $3.71M | $3.88M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $102.04M | $106.91M | $89.24M | $81.34M | $90.39M | $101.64M | $34.56M | $31.01M | $37.76M | $27.29M |
| Total assets | $115.61M | $120.71M | $98.73M | $94.05M | $102.70M | $114.83M | $48.47M | $48.00M | $45.07M | $36.72M |
| Current assets | $109.40M | $113.95M | $91.56M | $85.86M | $94.24M | $106.01M | $38.93M | $45.29M | $41.64M | $32.02M |
| Total liabilities | $334.27M | $398.86M | $286.49M | $117.56M | $55.58M | $109.16M | $69.85M | $42.33M | $39.01M | $6.58M |
| Current liabilities | $9.01M | $9.56M | $9.93M | $6.53M | $5.74M | $10.58M | $7.32M | $6.12M | $5.98M | $6.18M |
| Total equity incl. NCI | -$218.66M | -$278.15M | -$187.76M | -$23.52M | $47.11M | $5.67M | -$21.38M | $5.67M | $6.06M | $30.14M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $5.00M | $5.00M | $0 | $2.32M | $2.32M | $2.13M | $2.04M | $12.20M | $2.11M | $2.13M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $1.07M | $889.00K | $728.00K | $538.00K | $354.00K | $302.00K | $306.00K | $276.00K | $173.00K | $131.00K |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.42M | -$12.50M | -$5.81M | -$9.04M | -$6.11M | -$9.28M | $3.48M | -$6.75M | -$5.61M | -$8.75M |
| Capital expenditures | $19.00K | $120.00K | $59.00K | $24.00K | $18.00K | $27.00K | $19.00K | $0 | $0 | $7.00K |
| Investing cash flow | -$19.00K | -$120.00K | -$59.00K | -$24.00K | -$18.00K | -$27.00K | -$19.00K | $0 | $0 | -$7.00K |
| Financing cash flow | $2.51M | $30.28M | $13.78M | $9.00K | -$5.12M | $76.39M | $91.00K | -$1.00K | $16.09M | $0 |
| Net change in cash | -$4.92M | $17.66M | $7.91M | -$9.06M | -$11.26M | $67.08M | $3.55M | -$6.75M | $10.48M | -$8.75M |
| Stock-based compensation | $2.89M | $2.10M | $1.00M | $1.00M | $994.00K | $834.00K | $900.00K | $1.04M | $1.14M | $1.03M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $51.00K | $65.00K | $45.00K | $61.00K | $137.00K | $294.00K | $322.00K | $342.00K | $386.00K | $392.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$7.43M | -$12.62M | -$5.87M | -$9.06M | -$6.13M | -$9.31M | $3.46M | -$6.75M | -$5.61M | -$8.75M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | -207.4% | -209.1% | -2393.8% | -1107.3% | -917.3% | -971.6% | -1311.8% | 12.3% | Unavailable | Unavailable |
| FCF margin | -148.7% | -252.3% | -1111.9% | -922.1% | -623.7% | -946.7% | 528.5% | -67.5% | Unavailable | Unavailable |
| SBC / revenue | 57.9% | 42.1% | 189.8% | 102.2% | 101.1% | 84.8% | 137.4% | 10.4% | Unavailable | Unavailable |
| Current ratio | 12.14x | 11.91x | 9.22x | 13.15x | 16.41x | 10.02x | 5.32x | 7.40x | 6.96x | 5.18x |
| Revenue YoY growth | 408.6% | 408.6% | -19.4% | -90.2% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net margin | 1003.5% | -2550.1% | -34689.2% | -7288.2% | 4043.3% | -2743.6% | -4280.8% | -14.3% | Unavailable | Unavailable |
| R&D / revenue | 169.7% | 186.6% | 1702.8% | 790.8% | 614.6% | 667.1% | 816.8% | 52.0% | Unavailable | Unavailable |
| CapEx / revenue | 0.4% | 2.4% | 11.2% | 2.4% | 1.8% | 2.7% | 2.9% | 0.0% | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SRZN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.